The Immune Brain. IBOS.
One command, multiple co-operative therapies.
Combination Immunotherapy solved
Efficacy. Safety. Economics. Access.
Starts in cancer. Built to scale.
What we built
An Immune Brain. IBOS.
One command, multiple co-operative therapies.
A backbone for complex immune programming.
At vivo.
Setting the mRNA tumblers for solid tumors
We select the proven therapies each tumor needs and combine them into an mRNA program. The coordinated combination therapy the field has been missing.
IBOS: Physiological priming of the myeloid compartment
We wake the immune system’s own command center. Post leukapheresis, myeloid cells in the patient’s blood are activated through interaction with autologous platelets, nothing artificial. The only compartment biologically built to turn all tumblers at once. Within minutes, in the hospital apheresis unit.
IBOS: At Vivo programming of the myeloid compartment
Now we program the fix. The mRNA codes multiple attack vectors at once. Combinations written into the cells in a single step. A few hours, at the bedside. Because you can’t reprogram a system while it’s under attack.
In vivo reconditioning of immunity and the tumor microenvironment
The programmed myeloid cells traffic to the tumor and the lymph nodes and deliver every therapy locally and in coordination. A Trojan horse with a multiplex payload: T cells primed on site, immune modulators released, the niche reclaimed. Not therapies fighting alone: one coordinated attack, every part turning together.
Our origin story
40 years ago at Yale, Prof. Richard Edelson activated the body’s immune Operating System — by serendipity. The mRNA revolution has made it programmable
The Discovery
Rare T-Cell Lymphoma patients with a terminal diagnosis.
Dr. Richard Edelson, Professor at Yale University, pioneered the use of Extracorporeal Photochemotherapy (ECP) which led to unexpected durable remission.
The 35 years wait
Why ECP worked: platelet-activated myeloid cells meeting tumor antigen. But solid tumors need more. All five tumblers coordinated. At once. Multiplex attack. The technology just didn’t exist.
Exploiting the mRNA Revolution
Backed by the Gates Foundation. A five-year mRNA build with Prof. Santangelo at Emory. A technology able to load activate myeloid cells with a broad, immunomodulatory payload, including antigen, checkpoints, cytokines and co-stimulation.
How we do it?
ECP signposts an entirely novel category of cell therapy. At Vivo.
The At Vivo Concept
You can’t reprogram a system when its under attack. Build an immunological “pit stop” to allow ultra-rapid, complex programming at the bedside in a matter of hours.
Beyond the Ex-Vivo vs. In-Vivo Debate
Myeloid programming doesn’t need to choose a side. COGs closer to in vivo price points.
Yet control and safety of an ex vivo procedure maintained.
The payoff?
Best of both worlds. A controllable cellular therapy with a pathway to high-gross margins and a profitable distribution model for hospitals.
The change
The IBOS vision – where everyone wins
- Efficacy
- Safety
- Patient Access
- Economics
- Combinations → durable response + higher response rates.
- Multiple therapies. One format.
- Local delivery has the potential to reduce serious immune-related AEs
- Safety as format. Not as tradeoff.
- Safety promotes a first-line profile. Outpatient delivery becomes a future possibility.
- Multiple “drugs” combined in one treatment.
- Pre-screening allows patient qualification as a “responder”
- Curative potential insures against value-based outcomes pricing
- Anticipated safety profile creates opportunity for profitable distribution model